Salipro Biotech AB, a Swedish biotech company, has entered into a research collaboration and license agreement with Sanofi for the discovery of therapeutic biologics against a challenging drug target.   The collaboration leverages Salipro’s expertise in developing stable antigens of GPCRs, ion channels and transporters via its Salipro platform with Sanofi’s discovery programs to identify biologics with the desired therapeutic properties against a selected target.   “We are ...